Nikhil C. Munshi
YOU?
Author Swipe
View article: Figure S1 from Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel
Figure S1 from Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel Open
Consort Diagram
View article: Figure S2 from Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel
Figure S2 from Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel Open
Landmark PFS
View article: Distinct populations of vascular smooth muscle and sinoatrial progenitors are localized adjacent to pro-epicardium
Distinct populations of vascular smooth muscle and sinoatrial progenitors are localized adjacent to pro-epicardium Open
The developmental potential of cells adjacent to pro-epicardial (PE) cells (pro-EpiCs) that also express pro-EpiC markers is unknown. We apply single-cell mRNA deep sequencing paired with RNAScope validation, bioinformatic analysis, and li…
View article: The impact of Duffy genotype on progression-free survival (PFS) with lenalidomide, Bortezomib, and dexamethasone (RVd) alone or RVd plus autologous stem cell transplantation (ASCT) and continuous R maintenance in patients (pts) with newly diagnosed multiple myeloma (NDMM): Updated subgroup analysis of the phase 3 DETERMINATION trial
The impact of Duffy genotype on progression-free survival (PFS) with lenalidomide, Bortezomib, and dexamethasone (RVd) alone or RVd plus autologous stem cell transplantation (ASCT) and continuous R maintenance in patients (pts) with newly diagnosed multiple myeloma (NDMM): Updated subgroup analysis of the phase 3 DETERMINATION trial Open
Background: A single nucleotide polymorphism (SNP) in ACKR1/DARC results in erythrocyte Duffy null phenotype in ~66% of African American (AA) and <1% of White pts. This is associated with lower absolute neutrophil count (ANC) and has a …
View article: Retrospective real-world data analysis of morbidity burden and healthcare costs in idiopathic multicentric castleman disease compared with matched controls (BURDEN-iMCD)
Retrospective real-world data analysis of morbidity burden and healthcare costs in idiopathic multicentric castleman disease compared with matched controls (BURDEN-iMCD) Open
Introduction: Idiopathic multicentric Castleman disease (iMCD) is a rare, cytokine-driven hematologic disorder characterized by diffuse lymphadenopathy and systemic inflammation. Prior studies have suggested increased rates of hematologic …
View article: The endogenous T cell landscape is reshaped by CAR-T cell therapy and predicts treatment response in multiple myeloma
The endogenous T cell landscape is reshaped by CAR-T cell therapy and predicts treatment response in multiple myeloma Open
View article: Distinct patient, tumour and chimeric antigen receptor T‐cell characteristics are associated with initiating versus sustaining responses to idecabtagene vicleucel in relapsed and refractory multiple myeloma
Distinct patient, tumour and chimeric antigen receptor T‐cell characteristics are associated with initiating versus sustaining responses to idecabtagene vicleucel in relapsed and refractory multiple myeloma Open
Summary Idecabtagene vicleucel (ide‐cel), a B‐cell maturation antigen (BCMA)‐directed autologous chimeric antigen receptor (CAR) T‐cell therapy, was studied in relapsed and refractory multiple myeloma after >4 prior lines of therapy in Kar…
View article: Bedaquiline Amplifies Proteasome Inhibitor Efficacy and Overcomes Resistance in Multiple Myeloma
Bedaquiline Amplifies Proteasome Inhibitor Efficacy and Overcomes Resistance in Multiple Myeloma Open
Proteasome inhibitors (PIs) are cornerstone therapies for multiple myeloma (MM), yet resistance remains a major barrier to durable responses. To identify druggable vulnerabilities that enhance PIs efficacy, we performed a small-molecule ch…
View article: Prospective study of immunogenicity to SARS-CoV-2 booster vaccines in multiple myeloma and Waldenström macroglobulinemia
Prospective study of immunogenicity to SARS-CoV-2 booster vaccines in multiple myeloma and Waldenström macroglobulinemia Open
Patients with multiple myeloma (MM) and Waldenström macroglobulinemia (WM) have increased risk of severe coronavirus disease 2019. Impaired humoral responses to the primary vaccination series against severe acute respiratory syndrome coron…
View article: 888 | HEALTHCARE RESOURCE UTILIZATION AND COSTS IN THE MANAGEMENT OF PATIENTS WITH IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE IN THE UNITED STATES
888 | HEALTHCARE RESOURCE UTILIZATION AND COSTS IN THE MANAGEMENT OF PATIENTS WITH IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE IN THE UNITED STATES Open
View article: Supplementary Figure S1 from Targeting Acetyl-CoA Carboxylase Suppresses <i>De Novo</i> Lipogenesis and Tumor Cell Growth in Multiple Myeloma
Supplementary Figure S1 from Targeting Acetyl-CoA Carboxylase Suppresses <i>De Novo</i> Lipogenesis and Tumor Cell Growth in Multiple Myeloma Open
Supplementary Figure S1. Expression profiling and correlation analysis of MYC and ACC1 in patients with newly diagnosed multiple myeloma (NDMM).
View article: Supplementary Figure S5 from Targeting Acetyl-CoA Carboxylase Suppresses <i>De Novo</i> Lipogenesis and Tumor Cell Growth in Multiple Myeloma
Supplementary Figure S5 from Targeting Acetyl-CoA Carboxylase Suppresses <i>De Novo</i> Lipogenesis and Tumor Cell Growth in Multiple Myeloma Open
Supplementary Figure S5. Gene set enrichment analysis in MM cells following ND-646 treatment, and evaluation of cell growth under combined treatment with ND-646 and simvastatin.
View article: Data from Targeting Acetyl-CoA Carboxylase Suppresses <i>De Novo</i> Lipogenesis and Tumor Cell Growth in Multiple Myeloma
Data from Targeting Acetyl-CoA Carboxylase Suppresses <i>De Novo</i> Lipogenesis and Tumor Cell Growth in Multiple Myeloma Open
Purpose:In multiple myeloma, tumor cells reprogram metabolic pathways to sustain growth and monoclonal immunoglobulin production. This study examines acetyl-CoA carboxylase 1 (ACC1), the enzyme driving the rate-limiting step in d…
View article: Supplementary Figure S2 from Targeting Acetyl-CoA Carboxylase Suppresses <i>De Novo</i> Lipogenesis and Tumor Cell Growth in Multiple Myeloma
Supplementary Figure S2 from Targeting Acetyl-CoA Carboxylase Suppresses <i>De Novo</i> Lipogenesis and Tumor Cell Growth in Multiple Myeloma Open
Supplementary Figure S2. Quantitative analysis of ACACA expression in multiple myeloma (MM) cell lines.
View article: Supplementary Figure S4 from Targeting Acetyl-CoA Carboxylase Suppresses <i>De Novo</i> Lipogenesis and Tumor Cell Growth in Multiple Myeloma
Supplementary Figure S4 from Targeting Acetyl-CoA Carboxylase Suppresses <i>De Novo</i> Lipogenesis and Tumor Cell Growth in Multiple Myeloma Open
Supplementary Figure S4. Impact of pharmacological inhibition (ND-630 and ND-646) and ACC1 knockdown on MM cell viability, proliferation, and de novo lipogenesis (DNL) rates in MYC overexpressed MM cells.
View article: Supplementary Figure S3 from Targeting Acetyl-CoA Carboxylase Suppresses <i>De Novo</i> Lipogenesis and Tumor Cell Growth in Multiple Myeloma
Supplementary Figure S3 from Targeting Acetyl-CoA Carboxylase Suppresses <i>De Novo</i> Lipogenesis and Tumor Cell Growth in Multiple Myeloma Open
Supplementary Figure S3. Representative western blot analysis showing protein levels of ACC1, phosphorylated ACC (pACC), and MYC in MM cells.
View article: CD56 expression modulates NAD+ metabolic landscape and predicts sensitivity to anti-CD38 therapies in multiple myeloma
CD56 expression modulates NAD+ metabolic landscape and predicts sensitivity to anti-CD38 therapies in multiple myeloma Open
View article: The Evolution and Subtypes of Waldenstrom Macroglobulinemia: Findings from a Multi-omic Analysis of 249 Treatment Naive MYD88L265P Mutated Patients.
The Evolution and Subtypes of Waldenstrom Macroglobulinemia: Findings from a Multi-omic Analysis of 249 Treatment Naive MYD88L265P Mutated Patients. Open
To study the heterogeneity of transcriptional and genomic traits that underlie the clinical presentation of untreated Waldenstrom’s Macroglobulinemia (WM), we performed multi-omic studies in 249 treatment-naive patients with WM. For all pa…
View article: Nivolumab to restore T-cell fitness in CAR-T refractory multiple myeloma
Nivolumab to restore T-cell fitness in CAR-T refractory multiple myeloma Open
View article: Lymphopenia predicts poor outcomes in newly diagnosed multiple myeloma
Lymphopenia predicts poor outcomes in newly diagnosed multiple myeloma Open
Bone marrow microenvironment plays an important role in promoting growth and survival of multiple myeloma (MM) cells. The tumor-promoting immune microenvironment is augmented while antitumor immune responses are inhibited. Although clinica…
View article: Retraction Note: SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide
Retraction Note: SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide Open
View article: EASIX-guided risk stratification for complications and outcome after CAR T-cell therapy with ide-cel in relapsed/refractory multiple myeloma
EASIX-guided risk stratification for complications and outcome after CAR T-cell therapy with ide-cel in relapsed/refractory multiple myeloma Open
Background Chimeric antigen receptor (CAR) T-cell therapy has demonstrated significant benefits in the treatment of relapsed/refractory multiple myeloma (RRMM). However, these outcomes can be compromised by severe complications, including …
View article: Correction: Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401
Correction: Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401 Open
View article: Table S5 from Time-dependent prognostic value of serological and measurable residual disease assessments after idecabtagene vicleucel
Table S5 from Time-dependent prognostic value of serological and measurable residual disease assessments after idecabtagene vicleucel Open
number samples with inferior limit of MRD
View article: Data from Randomized Trial of a Personalized Dendritic Cell Vaccine after Autologous Stem Cell Transplant for Multiple Myeloma
Data from Randomized Trial of a Personalized Dendritic Cell Vaccine after Autologous Stem Cell Transplant for Multiple Myeloma Open
Purpose: Vaccination with dendritic cell (DC)/multiple myeloma (MM) fusions has been shown to induce the expansion of circulating MM-reactive lymphocytes and consolidation of clinical response following autologous hematopoietic cell transp…
View article: Figure S2 from Time-dependent prognostic value of serological and measurable residual disease assessments after idecabtagene vicleucel
Figure S2 from Time-dependent prognostic value of serological and measurable residual disease assessments after idecabtagene vicleucel Open
Landmark PFS
View article: Table S4 from Time-dependent prognostic value of serological and measurable residual disease assessments after idecabtagene vicleucel
Table S4 from Time-dependent prognostic value of serological and measurable residual disease assessments after idecabtagene vicleucel Open
HR and P values for landmark PFS within first year
View article: Study Representativeness Table1 from Randomized Trial of a Personalized Dendritic Cell Vaccine after Autologous Stem Cell Transplant for Multiple Myeloma
Study Representativeness Table1 from Randomized Trial of a Personalized Dendritic Cell Vaccine after Autologous Stem Cell Transplant for Multiple Myeloma Open
Study representation of underserved communities
View article: Table S2 from Time-dependent prognostic value of serological and measurable residual disease assessments after idecabtagene vicleucel
Table S2 from Time-dependent prognostic value of serological and measurable residual disease assessments after idecabtagene vicleucel Open
HR for PFS according to MRD status
View article: Figure S2 from Time-dependent prognostic value of serological and measurable residual disease assessments after idecabtagene vicleucel
Figure S2 from Time-dependent prognostic value of serological and measurable residual disease assessments after idecabtagene vicleucel Open
Landmark PFS